Exhibit 10.7





 


EXCHANGE AGREEMENT


 


THIS EXCHANGE AGREEMENT
(the “Agreement”) is dated this 30th day of September, 2015, by and among AMARANTUS BIOSCIENCE HOLDINGS,
INC., a Nevada corporation (the “Company”), all of the subsidiaries of the Company that are party to the Agreement
(collectively, “Subsidiaries”), and DOMINION CAPITAL LLC (the “Holder”).


 


WHEREAS, the Holder
beneficially owns and holds certain Senior Secured Convertible Promissory Notes, as set forth on Exhibit A hereto (the “Securities”);
and


 


WHEREAS, the Holder
desires to exchange (the “Exchange”) the Securities for new 12% Senior Secured Convertible Promissory Notes
and Warrants to purchase Common Stock (the “Exchange Securities”) of the Company as set forth and memorialized
on Exhibit B hereto, and the Company desires to issue the Exchange Securities in exchange for the Securities, all on the
terms and conditions set forth in this Agreement in reliance on the exemption from registration provided by Section 3(a)(9) of
the Securities Act of 1933, as amended (the “Securities Act”).


 


NOW, THEREFORE, in
consideration of the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Company and the Holder hereby agree as follows:


 


Section 1.  Exchange.  Subject
to and upon the terms and conditions set forth in this Agreement, the Holder agrees to surrender to the Company the Securities
and, in exchange therefore, the Company shall issue to the Holder the Exchange Securities.


 


1.1  Closing.  On
the Closing Date (as defined below), the Company will issue and deliver (or cause to be issued and delivered) the Exchange Securities
to the Holder, or in the name of a custodian or nominee of the Holder, or as otherwise requested by the Holder in writing, and
the Holder will surrender to the Company the Securities.  The closing of the Exchange shall occur on September 30, 2015,
or as soon thereafter as the parties may mutually agree in writing (the “Closing Date”), subject to the provisions
of Section 4 and Section 5 herein.


 


1.2  Section
3(a)(9).  Assuming the accuracy of the representations and warranties of each of the Company and the Holder set forth
in Sections 2 and 3 of this Agreement, the parties acknowledge and agree that the purpose of such representations and warranties
is, among other things, to ensure that the Exchange qualifies as an exchange of securities under Section 3(a)(9) of the Securities
Act.


 


Section 2.  Representations
and Warranties of the Company.  The Company represents and warrants to the Holder that:


 




    	 	1



     


    

 


2.1  Organization
and Qualification.  The Company and each of the subsidiaries of the Company (the “Subsidiaries”)
is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry
on its business as currently conducted.  Neither the Company, nor any Subsidiary is in violation or default of any of
the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.  Each
of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to
result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement or any documents executed
in connection herewith (the “Transaction Documents”), (ii) a material adverse effect on the results of operations,
assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)
a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under
any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no proceeding has been
instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.


 


2.2  Authorization;
Enforcement.  The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder.  The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders
in connection herewith or therewith other than in connection with the Required Approvals (as defined below).  This Agreement
and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company
and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company
enforceable against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.


 




    	 	2



     


    

 


2.3  Issuance
of Exchange Securities.  The issuance of the Exchange Securities is duly authorized and, upon issuance in accordance
with the terms hereof, the Exchange Securities shall be validly issued, fully paid and non-assessable. The shares of Common Stock
issued upon conversion of the Exchange Securities, when issued and delivered in accordance with the terms of the Exchange Securities,
will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens (as defined below) imposed by the Company,
other than restrictions on transfer under applicable state and federal securities laws.  The shares of Common Stock issued
upon exercise of the Exchange Securities, when issued and delivered in accordance with the terms of the Exchange Securities for
the consideration expressed therein, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens
imposed by the Company, other than restrictions on transfer under applicable state and federal securities laws.   Upon
issuance in accordance herewith, the issuance by the Company of the Exchange Securities is exempt from the registration requirements
of the Securities Act under Section 3(a)(9) of the Securities Act and all of the shares of Common Stock issuable upon conversion
of the Exchange Securities and upon exercise of the Exchange Securities will be freely transferable and freely tradable by the
Holder without restriction pursuant to Rule 144 of the Securities Act, assuming the Holder is not an Affiliate and the holding
period requirements of Rule 144 have been met. The shares of Common Stock issuable upon conversion or exercise, as applicable,
of the Exchange Securities shall not bear any restrictive or other legends or notations. The Company has reserved from its duly
authorized capital stock a number of shares of Common Stock for issuance of the shares underlying the Exchange Securities at least
equal to 300% of the Required Minimum on the date hereof. “Required Minimum” means, as of any date, the maximum
aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant to the Transaction Documents,
including any shares of Common Stock issuable upon exercise in full of all Exchange Securities or conversion in full of all Exchange
Securities (including shares of Common Stock issuable as payment of interest on the Exchange Securities), ignoring any conversion
or exercise limits set forth therein, and assuming that the Conversion Price or Exercise Price, as applicable, is at all times
on and after the date of determination 75% of the then Conversion Price or Exercise Price, as applicable, on the Trading Day immediately
prior to the date of determination.


 


2.4  No
Conflicts.  The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance of the Exchange Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any options, contracts,
agreements, liens, security interests, or other encumbrances (“Liens”) upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary
debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of
the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.


 




    	 	3



     


    

 


2.5  Acknowledgment
Regarding the Exchange.  The Company acknowledges and agrees that the Holder is acting solely in the capacity of
an arm’s length third party with respect to this Agreement and the transactions contemplated hereby.  The Company
further acknowledges the Holder is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to this Agreement and the transactions contemplated hereby, and any advice given by the Holder or any of their representatives
or agents in connection with this Agreement is merely incidental to the Exchange.


 


2.6  No
Commission; No Other Consideration.  The Company has not paid or given, and has not agreed to pay or give, directly
or indirectly, any commission or other remuneration for soliciting the Exchange.  The Exchange Securities are being issued
exclusively for the exchange of the Securities and no other consideration has or will be paid for the Exchange Securities.


 


2.7  3(a)(9)
Representation.  The Company has not, nor has any person acting on its behalf, directly or indirectly made any offers
or sales of any security or solicited any offers to buy any security under circumstances that would cause the Exchange and the
issuance of the Exchange Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes
of the Securities Act which would prevent the Company from delivering the Exchange Securities to the Holder pursuant to Section
3(a)(9) of the Securities Act, nor will the Company take any action or steps that would cause the Exchange, issuance and delivery
of the Exchange Securities to be integrated with other offerings to the effect that the delivery of the Exchange Securities to
the Holder would be seen not to be exempt pursuant to Section 3(a)(9) of the Securities Act.


 


2.8  No
Third-party Advisors.  Other than legal counsel, the Company has not engaged any third parties to assist in the solicitation
with respect to the Exchange.


 




    	 	4



     


    

 


2.9  SEC
Reports; Financial Statements.  Except for the Company’s Form 10-K for the year ended December 31, 2013, the
Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities
Act and the Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d)
of the Exchange Act, for the two years preceding the date hereof (or such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  As
of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC
Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect
thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with United States
generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.


 


2.10  Subsidiaries.  All
of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports.  The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities.  If the Company has no subsidiaries, all other
references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.


 


2.11  Filings,
Consents and Approvals.  Other than as set forth on Schedule 2.11, the Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal,
state, local or other governmental authority or any natural person, firm, partnership, association, corporation, company,
trust, business trust or other entity (each, a “Person”) in connection with the
execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the notice and/or application(s)
to each applicable Trading Market for the issuance and the listing of the shares of Common Stock issuable upon conversion of the
Exchange Securities and the shares of Common Stock issuable upon exercise of the Exchange Securities for trading thereon in the
time and manner required thereby, and (ii) the filing of Form D with the SEC and such filings as are required to be made under
applicable state securities laws (collectively, the “Required Approvals”). 


 




    	 	5



     


    

 


2.12  Capitalization.  The
capitalization of the Company is as set forth on Schedule 2.12.  No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.  Other
than as set forth on Schedule 2.12 or as set forth in the SEC Reports, there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock,
or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. All
of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities.  No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance of the Exchange Securities.  There
are no stockholder agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.


 


2.13  DTC
Eligibility.  The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities
Transfer (FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities
Transfer (FAST) Program. 


 


2.14  Material
Changes; Undisclosed Events, Liabilities or Developments.  Since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i)
there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or disclosed in filings made with the SEC, (iii) the Company has not altered
its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its
stockholder or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company
has not issued any equity securities to any officer, director or Affiliate (as defined below), except pursuant to existing Company
stock option plans. The Company does not have pending before the SEC any request for confidential treatment of information.  Except
for the issuance of the Exchange Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, properties, operations, assets or financial condition, that would be required to be disclosed by
the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least 1 Trading Day prior to the date that this representation is made.


 




    	 	6



     


    

 


2.15  Litigation.  Other
than as set forth on Schedule 2.15 or as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation,
proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Exchange Securities or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.  Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  There has not been, and
to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any
current or former director or officer of the Company.  The SEC has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act.


 


2.16  Labor
Relations.  No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect.  None of the Company’s
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company
or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that their relationships with their employees are good.  To the knowledge of the
Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term
of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any
other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such
executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing
matters.  The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where
the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.


 




    	 	7



     


    

 


2.17  Compliance. Except
as set forth on Schedule 2.17, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event
has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it
or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment,
decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule,
ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws
relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor
matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.


 


2.18  Regulatory
Permits.  The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC
Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating
to the revocation or modification of any Material Permit.


 


2.19  Title
to Assets.  The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and
the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries,
(ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties and (iii) Liens held by the Holder.  Any
real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and
enforceable leases with which the Company and the Subsidiaries are in compliance.


 




    	 	8



     


    

 


2.20  Intellectual
Property.  Other than as set forth on Schedule 2.20 or as set forth in the SEC Reports, the Company and the
Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks,
trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights as described
in the SEC Reports as necessary or required for use in connection with their respective businesses and which the failure to so
have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).  None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from
the date of this Agreement.  Neither the Company nor any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have
a Material Adverse Effect.  To the knowledge of the Company, all such Intellectual Property Rights are enforceable and
there is no existing infringement by another Person of any of the Intellectual Property Rights.  The Company and its
Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.


 


2.21  Insurance. The
Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but
not limited to, directors and officers insurance coverage at least equal to the aggregate principal amount of the Exchange Securities.  Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.


 


2.22  Transactions
With Affiliates and Employees.  Except as set forth in the SEC Reports, none of the officers or directors of the
Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from providing for the borrowing of money from or lending of money to, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for: (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan
of the Company.


 




    	 	9



     


    

 


2.23  Sarbanes-Oxley;
Internal Accounting Controls.  The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the SEC thereunder that are effective as of the date hereof and as of the Closing Date.  The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed
in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the SEC’s rules and forms.  The Company’s certifying officers
have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of
the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).  The
Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date.  Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the
Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial
reporting of the Company and its Subsidiaries.


 


2.24  Certain
Fees.  Except as set forth in Schedule 2.24, no brokerage or finder’s fees or commissions are or will be payable
by the Company or any Subsidiaries to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents.


 


2.25  Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Exchange Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended.  The Company shall conduct its business in a manner so that it will not become an “investment company”
subject to registration under the Investment Company Act of 1940, as amended.


 


2.26  Registration
Rights.  Other than as disclosed in the SEC Reports, the Transaction Documents and as set forth on Schedule 2.26,
no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company
or any Subsidiaries.


 




    	 	10



     


    

 


2.27  Listing
and Maintenance Requirements.  The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating
terminating such registration.  Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding
the date hereof, received notice from the OTCBB or any other exchange or quotation service on which the Common Stock is or has
been listed or quoted (the “Trading Market”) to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is, and has no reason to
believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.


 


2.28  Application
of Takeover Protections.  The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter
documents) or the laws of its state of incorporation that is or could become applicable to the Holder as a result of the  Holder
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company’s issuance of the Exchange Securities pursuant to the Exchange.


 


2.29  Disclosure.  Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Holder or its agents or counsel with any information
that it believes constitutes or might constitute material, non-public information.  The Company understands and confirms
that the Holder will rely on the foregoing representation in effecting transactions in securities of the Company.  All
of the disclosure furnished by or on behalf of the Company to the Holder regarding the Company and its Subsidiaries, their respective
businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made, not misleading.  The press releases
disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made and when made, not misleading.  The Company acknowledges
and agrees that the Holder makes no nor has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3 hereof.


 




    	 	11



     


    

 


2.30  No
Integrated Offering. Assuming the accuracy of the Holder’s representations and warranties set forth in Section 3, neither
the Company, nor any of its Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause the Exchange to be integrated
with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities
under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities
of the Company are listed or designated.


 


2.31  Solvency.  The
Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and
amounts of cash to be payable on or in respect of its debt).    The SEC Reports set forth as of the date hereof
all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary
has commitments.  For the purposes of this Agreement, “Indebtedness” means (x) any liabilities for
borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business),
(y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same,
are, or should be, reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by endorsement
of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present
value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP.  Except
as set forth in the SEC Reports, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.


 


2.32  Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company or of any Subsidiary know of no basis for any such claim.


 


2.33  Foreign
Corrupt Practices.  Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made
by any person acting on its behalf of which the Company is aware) which is  in violation of law or (iv) violated in any
material respect any provision of FCPA.


 




    	 	12



     


    

 


2.34  No
Disagreements with Accountants and Lawyers.  There are no disagreements of any kind presently existing, or reasonably
anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the
Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s
ability to perform any of its obligations under any of the Transaction Documents.


 


2.35  Acknowledgment
Regarding Holder’s Exchange of Securities.  The Company acknowledges and agrees that the Holder is acting solely
in the capacity of an arm’s length party with respect to the Transaction Documents and the transactions contemplated thereby.


 


2.36  
Regulation M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the issuance or resale of any of the Exchange Securities or the shares of Common Stock into which the Exchange
Securities are convertible or exercisable, as applicable, (ii) sold, bid for, purchased, or paid any compensation for soliciting
purchases of, any of the Exchange Securities or the shares of Common Stock into which the Exchange Securities are convertible or
exercisable, as applicable, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company.


 


2.37  Office
of Foreign Assets Control.  Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).


 


2.38  Bank
Holding Company Act.  Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”).  Neither the Company nor any of its Subsidiaries or Affiliates owns
or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.  Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.


 




    	 	13



     


    

 


2.39  Money
Laundering.  The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.


 


Section 3.  Representations
and Warranties of the Holder.  The Holder represents and warrants, severally and not jointly, to the Company that:


 


3.1  Ownership
of the Securities.  The Holder is the legal and beneficial owner of the Securities.  The Holder paid for
the Securities, and has continuously held the Securities since its issuance or purchase.  The Holder, individually or
through an affiliate, owns the Securities outright and free and clear of any options, contracts, agreements, liens, security interests,
or other encumbrances.


 


3.2  No
Public Sale or Distribution.  The Holder is acquiring the Exchange Securities in the ordinary course of business
for its own account and not with a view toward, or for resale in connection with, the public sale or distribution thereof; provided,
however, that by making the representations herein, the Holder does not agree to hold any of the Exchange Securities or the shares
of Common Stock into which such securities are convertible or exercisable, as applicable, for any minimum or other specific term
and reserves the right to dispose of the Exchange Securities and the shares of Common Stock into which such securities are convertible
and exercisable at any time in accordance with an exemption from the registration requirements of the Securities Act and applicable
state securities laws.  The Holder does not presently have any agreement or understanding, directly or indirectly, with
any person to distribute, or transfer any interest or grant participation rights in, the Securities or the Exchange Securities.


 


3.3  Accredited
Investor and Affiliate Status.  The Holder is an “accredited investor” as that term is defined in Rule
501 of Regulation D under the Securities Act.  The Holder is not, and has not been, for a period of at least three months
prior to the date of this Agreement (a) an officer or director of the Company, (b) an “affiliate” of the Company (as
defined in Rule 144) (an “Affiliate”) or (c) a “beneficial owner” of more than 10% of the common
stock (as defined for purposes of Rule 13d-3 of the Exchange Act).


 


3.4  Reliance
on Exemptions.  The Holder understands that the Exchange is being made in reliance on specific exemptions from the
registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth
and accuracy of, and the Holder’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of the Holder set forth herein in order to determine the availability of such exemptions and the eligibility of the Holder to complete
the Exchange and to acquire the Exchange Securities.


 




    	 	14



     


    

 


3.5  Information.  The
Holder has been furnished with all materials relating to the business, finances and operations of the Company and materials relating
to the Exchange which have been requested by the Holder.  The Holder has been afforded the opportunity to ask questions
of the Company. Neither such inquiries nor any other due diligence investigations conducted by the Holder or its representatives
shall modify, amend or affect the Holder’s right to rely on the Company’s representations and warranties contained
herein.  The Holder acknowledges that all of the documents filed by the Company with the SEC under Sections 13(a), 14(a)
or 15(d) of the Exchange Act that have been posted on the SEC’s EDGAR site are available to the Holder, and the Holder has
not relied on any statement of the Company not contained in such documents in connection with the Holder’s decision to enter
into this Agreement and the Exchange.


 


3.6  Risk.  The
Holder understands that its investment in the Exchange Securities involves a high degree of risk.  The Holder is able
to bear the risk of an investment in the Exchange Securities including, without limitation, the risk of total loss of its investment.  The
Holder has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision
with respect to the Exchange.  There is no assurance that the Exchange Securities or any securities into which the Exchange
Securities may convert will continue to be quoted, traded or listed for trading or quotation on the OTCBB or on any other organized
market or quotation system.


 


3.7  No
Governmental Review.  The Holder understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement in connection with the Exchange or the fairness
or suitability of the investment in the Exchange Securities nor have such authorities passed upon or endorsed the merits of the
Exchange Securities.


 


3.8  Organization;
Authorization.  The Holder is duly organized, validly existing and in good standing under the laws of its state of
formation and has the requisite organizational power and authority to enter into and perform its obligations under this Agreement.


 


3.9  Validity;
Enforcement.  This Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder
and shall constitute the legal, valid and binding obligations of the Holder enforceable against the Holder in accordance with its
terms.  The execution, delivery and performance of this Agreement by the Holder and the consummation by the Holder of
the transactions contemplated hereby (including, without limitation, the irrevocable surrender of the Securities) will not result
in a violation of the organizational documents of the Holder.


 




    	 	15



     


    

 


3.10  Prior
Investment Experience.  The Holder acknowledges that it has prior investment experience, including investment in
securities of the type being exchanged, including the Securities and the Exchange Securities, and has read all of the documents
furnished or made available by the Company to it and is able to evaluate the merits and risks of such an investment on its behalf,
and that it recognizes the highly speculative nature of this investment.


 


3.11  Tax
Consequences.  The Holder acknowledges that the Company has made no representation regarding the potential or actual
tax consequences for the Holder which will result from entering into the Agreement and from consummation of the Exchange.  The
Holder acknowledges that it bears complete responsibility for obtaining adequate tax advice regarding the Agreement and the Exchange.


 


3.12  No
Registration, Review or Approval.  The Holder acknowledges, understands and agrees that the Exchange Securities are
being exchanged hereunder pursuant to an exchange offer exemption under Section 3(a)(9) of the Securities Act.


 


Section 4.  Conditions
Precedent to Obligations of the Company.  The obligation of the Company to consummate the transactions contemplated
by this Agreement is subject to the satisfaction of each of the following conditions, provided that these conditions are for the
Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing the Holder with prior
written notice thereof:


 


4.1  Delivery.  The
Holder shall have delivered to the Company the Securities.


 


4.2  No
Prohibition.  No order of any court, arbitrator, or governmental or regulatory authority shall be in effect which
purports to enjoin or restrain any of the transactions contemplated by this Agreement; and


 


4.3  Representations.  The
accuracy in all material respects when made and on the applicable Closing Date of the representations and warranties of the Holder
contained herein (unless as of a specific date therein);


 


Section 5.  Conditions
Precedent to Obligations of the Holder.  The obligation of the Holder to consummate the transactions contemplated
by this Agreement is subject to the satisfaction of each of the following conditions, provided that these conditions are for the
Holder’s sole benefit and may be waived by the Holder at any time in its sole discretion by providing the Company with prior
written notice thereof:


 


5.1  No
order of any court, arbitrator, or governmental or regulatory authority shall be in effect which purports to enjoin or restrain
any of the transactions contemplated by this Agreement;  


 




    	 	16



     


    

 


5.2  the
representations and warranties of the Company (i) shall be true and correct in all material respects when made and on the applicable
Closing Date (unless as of a specific date therein) for such representations and warranties contained herein that are not qualified
by “materiality” or “Material Adverse Effect” and (ii) shall be true and correct when made and on the applicable
Closing Date (unless as of specific date therein) for such representations and warranties contained herein that are qualified by
“materiality” or “Material Adverse Effect”;


 


5.3  all
obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall
have been performed; and


 


5.4  from
the date hereof to the relevant Closing Date, trading in the Company’s common stock shall not have been suspended by the
SEC or any Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any trading market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of the Holder makes it impracticable or inadvisable to purchase the Exchange Securities at
the closing.


 


Section 6.  Holding
Period.  For the purposes of Rule 144 of the Securities Act, the Company acknowledges that the holding period of
the Exchange Securities may be tacked on the holding period of the Securities, and the Company agrees not to a position contrary
to this Section 6.


 


Section 7.  Governing
Law; Jurisdiction; Waiver of Jury Trial.  This Agreement shall be construed under the laws of the state of New York,
without regard to principles of conflicts of law or choice of law that would permit or require the application of the laws of another
jurisdiction.  The Company and the Holder each hereby agrees that all actions or proceedings arising directly or indirectly
from or in connection with this Agreement shall be litigated only in the Supreme Court of the State of New York or the United States
District Court for the Southern District of New York located in New York County, New York.  The Company and the Holder
each consents to the exclusive jurisdiction and venue of the foregoing courts and consents that any process or notice of motion
or other application to either of said courts or a judge thereof may be served inside or outside the State of New York or the Southern
District of New York by generally recognized overnight courier or certified or registered mail, return receipt requested, directed
to such party at its or his address set forth below (and service so made shall be deemed “personal service”) or by
personal service or in such other manner as may be permissible under the rules of said courts.  THE COMPANY AND THE HOLDER
EACH HEREBY WAIVES ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS AGREEMENT.


 




    	 	17



     


    

 


Section 8.  Counterparts.  This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if
the signature were an original, not a facsimile signature.


 


Section 9.  Headings.  The
headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.


 


Section 10.  Severability.  If
any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.


 


Section 11.  No
Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.


 


Section 12.  Entire
Agreement; Amendments.  This Agreement supersedes all other prior oral or written agreements between the Holder,
the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein
and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any representation,
warranty, covenant or undertaking with respect to such matters; provided, however, that all representations and warranties contained
in that certain Securities Purchase Agreement dated of September 30, 2015, covering the purchase of an identical senior secured
convertible promissory note to the Notes being issued hereunder shall be incorporated herein.  No provision of this Agreement
may be amended other than by an instrument in writing signed by the Company and the Holder.  No provision hereof may
be waived other than by an instrument in writing signed by the party against whom enforcement is sought.


 


Section 13.  Notices.  Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally; (b) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (c) one calendar day (excluding Saturdays, Sundays, and national banking holidays) after deposit with an overnight courier
service, in each case properly addressed to the party to receive the same.


 




    	 	18



     


    

 


The addresses and facsimile numbers for
such communications shall be:


 


If to the Company:


 


Amarantus Bioscience Holdings, Inc.


655 Montgomery Street – Suite 900


San Francisco, California 94111


Attn: Gerald Commissiong


 


If to the Holder:


 


Dominion Capital LLC


341 West 38th Street, Suite 800


New York NY 10018


Attn: Mikhail Gurevich


 


or to such other address and/or facsimile
number and/or to the attention of such other person as the recipient party has specified by written notice given to each other
party five (5) days prior to the effectiveness of such change.


 


Section 14.  Successors
and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns, including any purchasers of the Exchange Securities.  The Holder may assign some or all of its rights hereunder
without the consent of the Company, in which event such assignee shall be deemed to be the Holder hereunder with respect to such
assigned rights.


 


Section 15.  No
Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.


 


Section 16.  Survival
of Representations.  The representations and warranties of the Company and the Holder contained in Sections 2 and
3, respectively, will survive the closing of the transactions contemplated by this Agreement.


 


Section 17.  Further
Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.


 


[Signature Page Follows]


 




    	 	19



     


    

 


IN WITNESS WHEREOF, the parties have executed
this Exchange Agreement as of the date first written above.


 


AMARANTUS BIOSCIENCE HOLDINGS, INC.


 


	By:	 	 
	Name:	Gerald Commissiong	 
	Title:	Chief Executive Officer	 





	 	 	 
	Amarantus Therapeutics, Inc.  	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	Amarantus Therapeutics, Inc.  	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	Amarantus MA, Inc.  	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 





	DOMINION CAPITAL LLC	 
	 	 	 
	By:	 	 
	Name: 	 	 
	Title: 	 	 
	 	 	 
	By: 	 	 
	Name: 	 	 
	Title: 	 	 


 




     


     


    

 


Exhibit
A


 


Senior Secured Convertible Promissory
Notes


 


	 	 	Face Value	 	 	Make Whole	 	 	OID	 	 	Date
	Notes	 	$	2,500,000.00	 	 	$	150,000.00	 	 	$	0.00	 	 	2/24/2015
	 	 	$	350,000.00	 	 	$	21,000.00	 	 	$	0.00	 	 	3/31/2015
	Totals	 	$	2,850,000	 	 	$	171,000	 	 	$	0.00	 	 	 



 


Cumulative Total for Face Value, Make Whole, OID: $ 3,021,000.00



 




     


     


    

 


EXHIBIT B


 


Form of and Schedule of Exchanged Securities


 


	12% Senior Secured Convertible Promissory Note	 	$	3,021,000.00	 
	Common Stock Warrants	 	 	1,298,612	 



 




     


     


    

 


ANNEX A


 


NOTICE OF CONVERSION


 


The undersigned hereby
elects to convert principal, accrued but unpaid interest and/or any of amounts due under the 12% Senior Secured Convertible Promissory
Note due September 29, 2016 of Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”), into
shares of common stock (the “Common Stock”), of the Company according to the conditions hereof, as of the date
written below.  If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned
will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably
requested by the Company in accordance therewith.  No fee will be charged to the holder for any conversion, except for
such transfer taxes, if any.


 


By the delivery of
this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not
exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act.


 


The undersigned agrees
to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the
aforesaid shares of Common Stock, if the resale of any such shares of Common Stock are covered by and are being sold pursuant to
an effective Registration Statement.


 


Conversion calculations:


	 	Date to Effect Conversion:	 


 


	 	Principal Amount of Note to be Converted:	 


 


	 	Payment of Interest in Common
Stock __ yes  __ no
	 	If yes, $_____ of Interest Accrued
on Account of Conversion at Issue.


 





	 	Other Amounts Owed Under this Note to be Converted including Late Fees: ____________________________________







 





	 	Number of shares of Common Stock to be issued: 	 


 


	 	Signature:	 


 


	 	Name:	 


 


	 	Delivery Instructions:


 




     


     


    

 


Schedule 1


 


CONVERSION SCHEDULE


 


This 12% Senior Secured Convertible Promissory
Note due on September 29, 2016 in the original principal amount of $[_______] is issued by Amarantus Bioscience Holdings, Inc.,
a Nevada corporation.  This Conversion Schedule reflects conversions made under Section 4 of the above referenced Note.


 


Dated:


 


	Date of Conversion

(or for first entry,

Original Issue Date)	 	Amount of

Conversion	 	Aggregate

Principal

Amount

Remaining

Subsequent to

Conversion

(or original

Principal

Amount)	 	Company Attest
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 


 




     


     


    

 


SCHEDULES


 


Disclosure Schedules to Exchange Agreement
between Dominion Capital, LLC and Amarantus BioScience Holdings, Inc. September 4, 2015


 


Section 2.12 Capitalization:


 


	 	 	Fully Diluted	 
	Issued and outstanding	 	 	8,054,061	 
	Lincoln Park Capital	 	 	83,603	 
	Series C Convertible Preferred Stock	 	 	5,000	 
	Series E Convertible Preferred Stock	 	 	624,848	 
	Series G Convertible Preferred Stock	 	 	1,567,242	 
	Memory Dx	 	 	43,333	 
	Warrants	 	 	302,891	 
	 	 	 	 	 
	Total	 	 	10,680,978	 



 


Section 2.17 Compliance


 


Agreement and Plan of Merger by and among
Amarantus Bioscience Holdings, Inc., Neuro Acquisition Corporation, Diogenix, Inc. and Nerveda, LLC dated January 8, 2015, Section
4.12 Issuance and Registration of Parent Common Stock


 


Section 2.26 Registration Rights


 


Agreement and Plan of Merger by and among
Amarantus Bioscience Holdings, Inc., Neuro Acquisition Corporation, Diogenix, Inc. and Nerveda, LLC dated January 8, 2015, Section
4.12 Issuance and Registration of Parent Common Stock